- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04437862
A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke (EvaQ)
September 11, 2023 updated by: MIVI Neuroscience, Inc.
A Prospective, Multi-Center, Single Arm Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke: The EvaQ Study
Assess the safety and efficacy of the Q Revascularization System to remove thrombi and emboli from the neurovasculature in patients experiencing an acute ischemic stroke
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
121
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kelly Breuer
- Phone Number: 6617177669
- Email: kbreuer@mivineuro.com
Study Locations
-
-
-
Bordeaux, France, 33000
- Chu Pellegrin
-
Nancy, France, 54035
- CHU Urbains
-
Paris, France, 94270
- CHU Bicetre Paris
-
Toulouse, France, 31059
- Hopital Purpan
-
-
-
-
Florida
-
Tampa, Florida, United States, 33620
- University of South Florida
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Health Care
-
-
New York
-
Buffalo, New York, United States, 14208
- University at Buffalo Neurosurgery
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Baptist Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or older.
- Pre-stroke independent functional status in activities of daily living with mRS 0-1.
- A disabling stroke defined as NIHSS ≥ 6
- In USA thrombolytic therapy (IV tPA) received within 3 hours of onset/ last known well, in Europe treatment with IV tPA received within 4.5 hours from onset/ last known well OR ineligibility for thrombolytic therapy
- Endovascular treatment intended to be initiated < 8 hours from onset of symptoms or last known well time
- Confirmed symptomatic large vessel occlusion of the intracranial internal carotid artery, middle cerebral artery, M1, M2, basilar or intracerebral vertebral artery by baseline neuroimaging CTA/MRA and angiographic imaging with a mTICI Score 0-1
- For strokes in the anterior circulation the following imaging criteria should also be met: MRI criterion of volume of diffusion restriction visually assessed ≤50 mL OR CT criterion of ASPECTS 6 to 10 on baseline CT or CTA-source images or, significantly lowered cerebral blood volume (CBV) ≤50 mL
- For strokes in the basilar or vertebral artery, the following imaging criterion should also be met: pc-ASPECTS score 8 to 10 on baseline CT, CTA-source images, or MRI
- Signed informed consent from subject, acceptable person responsible (e.g. LAR) and/or according to County specific regulatory requirements and local ethical committee or review board requirements
Exclusion Criteria:
- CT or MRI evidence of intracranial hemorrhage on presentation
- CT or MRI showing mass effect or intracranial tumor (meningioma > 2 cm in diameter).
- Previous stroke within the past 3 months
- Rapidly improving neurological status as determined by Investigator/Neurologist
- Renal failure/insufficiency with >3.0 mg/dL creatinine prior to procedure
- Severe, sustained hypertension resistant to treatment (SBP >185 mmHg or DBP >110 mmHg)
- Use of warfarin anticoagulation with International Normalized Ratio (INR) > 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency
- For patients who have received a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) > 2.0 times the normal prior to procedure
- Platelet count < 50,000 mm3
- Cerebral vasculitis or evidence of active systemic infection
- Suspicion of aortic dissection, presumed septic embolus, or suspicion of bacterial endocarditis
- Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation)
- Seizure due to stroke
- Pregnancy
- Severe contrast allergy or absolute contraindication to iodinated contrast
- Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure
- Difficult endovascular access or difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy
- Evidence of dissection in the carotid or target artery for treatment
- Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic
- Active participation in another study involving an investigational drug or device
- A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient
- Unwillingness to complete follow up visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Q Revascularization System
|
Q Revascularization System for mechanical thrombectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful revascularization rate
Time Frame: Procedure end
|
Successful revascularization defined at modified Treatment in Cerebral Ischemia (mTICI) 2b-3 at the end of the procedure
|
Procedure end
|
Symptomatic intracranial haemorrhage rate
Time Frame: 36 hours post procedure
|
Symptomatic intracranial haemorrhage (ICH) as detected by CT/MRI and a clinical deterioration of NIHSS change ≥ 4
|
36 hours post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful revascularization rate with study device
Time Frame: Procedure
|
Successful revascularization defined as mTICI 2b-3 flow after all aspiration attempts with the study device
|
Procedure
|
Successful revascularization rate on the first attempt with study device
Time Frame: Procedure
|
Successful revascularization defined as mTICI 2b-3 flow after the first aspiration attempt with the study device
|
Procedure
|
Procedure Time
Time Frame: Procedure
|
Time from groin puncture to successful revascularization defined as final mTICI 2b-3 flow
|
Procedure
|
ENT rate
Time Frame: Procedure
|
Embolization to a new vascular territory (ENT) during procedure
|
Procedure
|
Procedure Complications
Time Frame: Procedure through 90 days
|
Rate of procedure related complications
|
Procedure through 90 days
|
ICH
Time Frame: 36 hours post procedure
|
Occurrence of all intracranial hemorrhage using the Heidelberg Bleeding Classification.
|
36 hours post procedure
|
Good functional outcome
Time Frame: 90 days post procedure
|
Good functional outcome measured by Modified Rankin Score (mRS) defined as a value of 0-2
|
90 days post procedure
|
Mortality
Time Frame: 90 days post procedure
|
All cause mortality
|
90 days post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christopher Cognard, PhD, MD, Hopital Purpan
- Principal Investigator: Lucas Elijovich, MD, University of Tennessee Health Sciences Center
- Principal Investigator: Brian Jankowitz, MD, School of Medicine at the University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2020
Primary Completion (Actual)
April 21, 2023
Study Completion (Actual)
August 2, 2023
Study Registration Dates
First Submitted
June 16, 2020
First Submitted That Met QC Criteria
June 16, 2020
First Posted (Actual)
June 18, 2020
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101773
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Cidat, S.A. de C.V.El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezUnknownStroke | Stroke, Acute | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, AcuteMexico
-
Centre hospitalier de l'Université de Montréal...Not yet recruitingStroke, Acute ThromboticCanada
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
University Hospital, MontpellierNot yet recruiting
-
Capital Medical UniversityRecruitingAcute Stroke | Ischemic Stroke, AcuteChina
-
Chonbuk National University HospitalKorean Society of Neurosonology; Ministry of SMEs and Startups, Republic of... and other collaboratorsCompleted
-
National Taiwan University HospitalCompleted
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of EdinburghNHS LothianRecruiting
Clinical Trials on Q Revascularization System
-
Emory UniversityGeorgia Tech Research Foundation; Georgia Clinical & Translational Science...Enrolling by invitationCOVID-19 | Acute Respiratory Distress SyndromeUnited States
-
University Hospital ErlangenCompletedEnd-stage Renal Disease | Critical Limb IschemiaGermany
-
Boston Scientific CorporationCompletedTachycardia, VentricularUnited States, Netherlands, New Zealand, United Kingdom
-
ECRI bvSiemens Healthineers AG; Pie Medical ImagingRecruitingCoronary Artery DiseaseGermany, Ireland, Italy, Netherlands, Spain, United Kingdom, France
-
Silk Road MedicalCompletedCarotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | Carotid DiseaseUnited States, Spain
-
Kenneth PalmerUnited States Department of DefenseRecruitingCOVID-19 PreventionUnited States
-
Federal State Budgetary Institution National Medical...Kemerovo Cardiology Center, Tarasov Roman Sergeevich; Tomsk National Research...RecruitingCoronary Syndrome, Acute, Non-ST Elevation, High Risk PatientsRussian Federation
-
Samsung Medical CenterChonnam National UniversityActive, not recruitingCancer | Acute Myocardial InfarctionKorea, Republic of
-
Consorzio Futuro in RicercaActive, not recruitingMyocardial InfarctionSpain, Italy, Poland
-
Silk Road MedicalRecruitingCarotid Artery DiseasesUnited States